Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic out- comes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118:1626 36. 619. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31:3006 16. 620. Waters DD, Walling A, Roy D, et al. Previous coronary artery bypass grafting as an adverse prognostic factor in unstable angina pectoris. Am J Cardiol. 1986;58:465 9. 621. Kleiman NS, Anderson HV, Rogers WJ, et al. Comparison of outcome of patientswithunstableanginaandnon-Q-waveacutemyocardialinfarction Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e409 with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). Am J Cardiol. 1996;77:227 31. 622. Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2002;105:322 7. 623. Brilakis ES, de Lemos JA, Cannon CP, et al. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008;102:552 8. 624. Labinaz M, Mathias J, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior percutaneous coronary interven- tion: a pooled analysis of three randomized clinical trials. Eur Heart J. 2005;26:128 36. 625. Kim MS, Wang TY, Ou FS, et al.


2005;26:128 36. 625. Kim MS, Wang TY, Ou FS, et al. Association of prior coronary artery bypass graft surgery with quality of care of patients with non-ST-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. Am Heart J. 2010;160:951 7. 626. Adesanya AO, de Lemos JA, Greilich NB, et al. Management of peri- operative myocardial infarction in noncardiac surgical patients. Chest. 2006;130:584 96. 627. Berger PB, Bellot V, Bell MR, et al. An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac sur- gery. Am J Cardiol. 2001;87:1100 2. A6, A9. 628. Bertrand ME, Lablanche JM, Tilmant PY, et al. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coro- nary arteriography. Circulation. 1982;65:1299 306. 629. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948 54. 630. Bugiardini R, Manfrini O, Pizzi C, et al. Endothelial function predicts futuredevelopmentofcoronaryarterydisease:astudyofwomenwithchest pain and normal coronary angiograms. Circulation. 2004;109:2518 23. 631. Gualandro DM, Calderaro D, Yu PC, et al. Acute myocardial infarction after noncardiac surgery. Arq Bras Cardiol. 2012;99:1060 7. 632. Gualandro DM, Yu PC, Calderaro D, et al. II Guidelines for periopera- tive evaluation of the Brazilian Society of Cardiology. Arq Bras Cardiol. 2011;96:1 68. 633. Villacorta JH, Castro IS, Godinho M, et al. B-type natriuretic peptide is predictive of postoperative events in orthopedic surgery. Arq Bras Cardiol. 2010; 95:743 8. 634. [Guidelines for unstable angina and non-ST-segment elevation myocar- dial infarction of the Brazilian Society of Cardiology (II Edition, 2007)]. Arq Bras Cardiol. 2007;89:e89 131. 635. Jaffe AS. Chasing troponin: how low can you go if you can see the rise? J Am Coll Cardiol. 2006;48:1763 4. 636.


Chasing troponin: how low can you go if you can see the rise? J Am Coll Cardiol. 2006;48:1763 4. 636. Devereaux PJ, Xavier D, Pogue J, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med. 2011;154:523 8. 637. Devereaux PJ, Chan MT, Alonso-Coello P, et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012;307:2295 304. 638. Kavsak PA, Walsh M, Srinathan S, et al. High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: a prospective cohort study. Clin Biochem. 2011;44:1021 4. 639. Levy M, Heels-Ansdell D, Hiralal R, et al. Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after non- cardiac surgery: a systematic review and meta-analysis. Anesthesiology. 2011;114:796 806. 640. Landesberg G, Shatz V, Akopnik I, et al. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. J Am Coll Cardiol. 2003;42: 1547 54. 641. Bursi F, Babuin L, Barbieri A, et al. Vascular surgery patients: periopera- tive and long-term risk according to theACC/AHA guidelines, the additive role of post-operative troponin elevation. Eur Heart J. 2005;26:2448 56. 642. Devereaux PJ, Goldman L, Yusuf S, et al. Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review. CMAJ. 2005;173:779 88. 643. Landesberg G, Beattie WS, Mosseri M, et al. Perioperative myocardial infarction. Circulation. 2009;119:2936 44. 644. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. Circulation. 2009;120:e169 276. 645. Devereaux PJ, Yang H, Yusuf S, et al.


2009;120:e169 276. 645. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release meto- prolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371:1839 47. 646. McFalls EO, Ward HB, Moritz TE, et al. Predictors and outcomes of a perioperative myocardial infarction following elective vascular surgery in patients with documented coronary artery disease: results of the CARP trial. Eur Heart J. 2008;29:394 401. 647. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977;297:845 50. 648. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospec- tive validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100:1043 9. 649. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarc- tion and renal dysfunction: a high-risk combination. Ann Intern Med. 2002;137:563 70. 650. Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137:555 62. 651. Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009;4:1032 43. 652. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal func- tion on the effects of early revascularization in non-ST-elevation myo- cardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009; 120:851 8. 653. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocar- dial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease.


Renal failure and acute myocar- dial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A col- laborative project of the United States Renal Data System/ National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163:399 406. 654. Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Estimated glomerular fil- tration rate, inflammation, and cardiovascular events after an acute coro- nary syndrome. Am Heart J. 2008;155:725 31. 655. Melloni C, Peterson ED, Chen AY, et al. Cockcroft-Gault versus modi- fication of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non- ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008;51:991 6. 656. Al SJ, Reddan DN, Williams K, et al. Prognostic implications of abnor- malities in renal function in patients with acute coronary syndromes. Circulation. 2002;106:974 80. 657. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285 95. 658. Velazquez EJ, Pfeffer MA, McMurray JV, et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in con- text. Eur J Heart Fail. 2003;5:537 44. 659. Skali H, Uno H, Levey AS, et al. Prognostic assessment of estimated glo- merular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J. 2011;162:548 54. 660. Laskey WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50:584 90. 661. Hare JM, Fishman JE, Gerstenblith G, et al.


2007;50:584 90. 661. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369 79. 662. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121:357 65. 663. Morel O, Muller C, Jesel L, et al. Impaired platelet P2Y12 inhibi- tion by thienopyridines in chronic kidney disease: mechanisms, clini- cal relevance and pharmacological options. Nephrol Dial Transplant. 2013;28:1994 2002. 664. Park SH, Kim W, Park CS, et al.A comparison of clopidogrel responsive- ness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104:1292 5. 665. Morel O, El GS, Jesel L, et al. Cardiovascular mortality in chronic kid- ney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011;57:399 408. 666. Woo JS, Kim W, Lee SR, et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high- maintenance dose of clopidogrel: results of the effect of platelet inhibi- tion according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J. 2011;162:1018 25. 667. Alexopoulos D, Panagiotou A, Xanthopoulou I, et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialy- sis and with high on-treatment platelet reactivity. J Thromb Haemost. 2011;9:2379 85. 668. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.


Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122:1056 67. 669. Hutchinson-Jaffe AB, Goodman SG, Yan RT, et al. Comparison of base- line characteristics, management and outcome of patients with non-ST- segment elevation acute coronary syndrome in versus not in clinical trials. Am J Cardiol. 2010;106:1389 96. 670. Akhter N, Milford-Beland S, Roe MT, et al. Gender differences among patients with acute coronary syndromes undergoing percuta- neous coronary intervention in the American College of Cardiology- National Cardiovascular Data Registry (ACC-NCDR). Am Heart J. 2009;157:141 8. 671. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syn- dromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/ American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol. 2005;45:832 7. 672. Lansky AJ, Mehran R, Cristea E, et al. Impact of gender and antithrom- bin strategy on early and late clinical outcomes in patients with non- ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol. 2009;103:1196 203. 673. Alexander KP, ChenAY, Newby LK, et al. Sex differences in major bleed- ing with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guide- lines) initiative. Circulation. 2006;114:1380 7. 674. Regitz-ZagrosekV, Blomstrom LC, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147 97. 675. Dey S, Flather MD, Devlin G, et al.


2011;32:3147 97. 675. Dey S, Flather MD, Devlin G, et al. Sex-related differences in the pre- sentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart. 2009;95:20 6. 676. Radovanovic D, Erne P, Urban P, et al. Gender differences in manage- ment and outcomes in patients with acute coronary syndromes: results on 20,290 patients from the AMIS Plus Registry. Heart. 2007;93:1369 75. 677. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol. 2009;54:1561 75. 678. Kaul P, Chang WC, Westerhout CM, et al. Differences in admission rates and outcomes between men and women presenting to emergency depart- ments with coronary syndromes. CMAJ. 2007;177:1193 9. 679. Sullivan AK, Holdright DR, Wright CA, et al. Chest pain in women: clinical, investigative, and prognostic features. BMJ. 1994;308:883 6. 680. Kreatsoulas C, Natarajan MK, Khatun R, et al. Identifying women with severe angiographic coronary disease. J Intern Med. 2010;268:66 74. 681. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical, character- istics, and mortality among patients with myocardial infarction present- ing without chest pain. JAMA. 2000;283:3223 9. 682. Gulati M, Cooper-DeHoff RM, McClure C, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med. 2009;169:843 50. 683. Truong QA, Murphy SA, McCabe CH, et al. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes. 2011;4:328 36. 684. Wiviott SD, Cannon CP, Morrow DA, et al.


2011;4:328 36. 684. Wiviott SD, Cannon CP, Morrow DA, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST- elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) sub- study. Circulation. 2004;109:580 6. 685. Diercks DB, Owen KP, Kontos MC, et al. Gender differences in time to presentation for myocardial infarction before and after a national women s cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). Am Heart J. 2010;160:80 7. 686. Jneid H, Fonarow GC, Cannon CP, et al. Sex differences in medi- cal care and early death after acute myocardial infarction. Circulation. 2008;118:2803 10. 687. Pauly DF, Johnson BD, Anderson RD, et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascu- lar dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women s Ischemia Syndrome Evaluation (WISE). Am Heart J. 2011;162:678 84. 688. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleed- ing in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556 66. 689. Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. Eur Heart J. 2004;25:1641 50. 690. Sidhu RB, Brown JR, Robb JF, et al. Interaction of gender and age on post cardiac catheterization contrast-induced acute kidney injury. Am J Cardiol.


Interaction of gender and age on post cardiac catheterization contrast-induced acute kidney injury. Am J Cardiol. 2008;102:1482 6. 691. Ohlow MA, Secknus MA, von KH, et al. Incidence and outcome of fem- oral vascular complications among 18,165 patients undergoing cardiac catheterisation. Int J Cardiol. 2009;135:66 71. 692. Lansky AJ, Costa RA, Mooney M, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery dis- ease. J Am Coll Cardiol. 2005;45:1180 5. 693. Ng VG, Lansky AJ, Hermiller JB, et al. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). Am J Cardiol. 2011;107:841 8. 694. Solinas E, Nikolsky E, Lansky AJ, et al. Gender-specific outcomes after sirolimus-eluting stent implantation. JAm Coll Cardiol. 2007;50:2111 6. 695. Bukkapatnam RN, Yeo KK, Li Z, et al. Operative mortality in women and men undergoing coronary artery bypass grafting (from the California Coronary Artery Bypass Grafting Outcomes Reporting Program). Am J Cardiol. 2010;105:339 42. 696. Kim C, Redberg RF, Pavlic T, et al. A systematic review of gender differ- ences in mortality after coronary artery bypass graft surgery and percuta- neous coronary interventions. Clin Cardiol. 2007;30:491 5. 697. Melloni C, Alexander KP, Chen AY, et al. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008;156:209 15. 698. LaPointe NM, ChenAY,Alexander KP, et al. Enoxaparin dosing and associ- ated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes.Arch Intern Med. 2007;167:1539 44. 699. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4:CD002042. ical practice guideline from the AABB. Ann Intern Med. 2012;157:49 58. 701. Rao SV, Jollis JG, Harrington RA, et al.


2012;157:49 58. 701. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfu- sion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555 62. 702. Alexander KP, Chen AY, Wang TY, et al. Transfusion practice and out- comes in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008;155:1047 53. 703. Yang X, Alexander KP, Chen AY, et al. The implications of blood trans- fusions for patients with non-ST-segment elevation acute coronary syn- dromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005;46:1490 5. 704. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemo- globin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111:2042 9. Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e411 705. Gonzalez-Ferrer JJ, Garcia-Rubira JC, Balcones DV, et al. Influence of hemoglobin level on in-hospital prognosis in patients with acute coro- nary syndrome. Rev Esp Cardiol. 2008;61:945 52. 706. Rousseau M, Yan RT, Tan M, et al. Relation between hemoglobin level and recurrent myocardial ischemia in acute coronary syndromes detected by continuous electrocardiographic monitoring. Am J Cardiol. 2010;106:1417 22. 707. Younge JO, Nauta ST, Akkerhuis KM, et al. Effect of anemia on short- and long-term outcome in patients hospitalized for acute coronary syn- dromes. Am J Cardiol. 2012;109:506 10. 708. Shu DH, Ransom TP, O Connell CM, et al. Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes. Cardiovasc Diabetol. 2006;5:8. 709. Levy PS, Quigley RL, Gould SA. Acute dilutional anemia and critical left anterior descending coronary artery stenosis impairs end organ oxy- gen delivery. J Trauma. 1996;41:416 23. 710. Most AS, Ruocco NA Jr., Gewirtz H. Effect of a reduction in blood vis- cosity on maximal myocardial oxygen delivery distal to a moderate coro- nary stenosis. Circulation.


Most AS, Ruocco NA Jr., Gewirtz H. Effect of a reduction in blood vis- cosity on maximal myocardial oxygen delivery distal to a moderate coro- nary stenosis. Circulation. 1986;74:1085 92. 711. Willis P, Voeltz MD. Anemia, hemorrhage, and transfusion in percutane- ous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol. 2009;104:34C 8C. 712. Ndrepepa G, Schuster T, Hadamitzky M, et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012;125:1424 31. 713. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syn- dromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32:1854 64. 714. Manoukian SV. Predictors and impact of bleeding complications in percu- taneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol. 2009;104:9C 15C. 715. Pham PA, Pham PT, Pham PC, et al. Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention. Vasc Health Risk Manag. 2011;7:551 67. 716. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1815 23. 717. Hochholzer W, Wiviott SD, Antman EM, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitionWith Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011;123:2681 9. 718. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30:1457 66. 719.


Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30:1457 66. 719. Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J. 2007;154:3 11. 720. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials proposal of a new classification. Am J Cardiol. 2007;99:288 90. 721. Schulman S, Kearon C. Definition of major bleeding in clinical inves- tigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692 4. 722. Rao SV, Eikelboom JA, Granger CB, et al. Bleeding and blood trans- fusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1193 204. 723. Cheng S, Morrow DA, Sloan S, et al. Predictors of initial nontherapeu- tic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation. 2009;119:1195 202. 724. Campbell CL, Steinhubl SR, Hooper WC, et al. Bleeding events are associated with an increase in markers of inflammation in acute coro- nary syndromes: an ACUITY trial substudy. J Thromb Thrombolysis. 2011;31:139 45. 725. Subherwal S, Bach RG, ChenAY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119:1873 82. 726. Chatterjee S, Wetterslev J, Sharma A, et al. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diver- sity-adjusted study sequential analysis. JAMA Intern Med. 2013;173:132 9. 727. Bassand JP, Hamm CW, Ardissino D, et al.


2013;173:132 9. 727. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598 660. 728. Oliveira GB, Crespo EM, Becker RC, et al. Incidence and prognostic sig- nificance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med. 2008;168:94 102. 729. Wang TY, Ou FS, Roe MT, et al. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in con- temporary clinical practice. Circulation. 2009;119:2454 62. 730. Hakim DA, Dangas GD, CaixetaA, et al. Impact of baseline thrombocyto- penia on the early and late outcomes after ST-elevation myocardial infarc- tion treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Am Heart J. 2011;161:391 6. 731. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppres- sion using integrilin therapy (PURSUIT) trial experience. Circulation. 1999;99:2892 900. 732. Dasgupta H, Blankenship JC, Wood GC, et al. Thrombocytopenia com- plicating treatment with intravenous glycoprotein IIb/IIIa receptor inhib- itors: a pooled analysis. Am Heart J. 2000;140:206 11. 733. Matthai WH Jr. Evaluation of thrombocytopenia in the acute coronary syndrome. Curr Opin Hematol. 2010;17:398 404. 734. Kilickiran AB, Oto A, Ozcebe O. Thrombocytopenia associated with antithrombotic therapy in patients with cardiovascular diseases: diagno- sis and treatment. Am J Cardiovasc Drugs. 2008;8:327 39. 735. Gore JM, Spencer FA, Gurfinkel EP, et al. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2009;103:175 80. 736. Yeh RW, Wiviott SD, Giugliano RP, et al.


2009;103:175 80. 736. Yeh RW, Wiviott SD, Giugliano RP, et al. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfraction- ated heparin in patients presenting with acute coronary syndromes. Am J Cardiol. 2007;100:1734 8. 737. Eikelboom JW, Anand SS, Mehta SR, et al. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study. Circulation. 2001;103:643 50. 738. Caixeta A, Dangas GD, Mehran R, et al. Incidence and clinical conse- quences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Am Heart J. 2011;161:298 306. 739. Lopes RD, Ohman EM, Granger CB, et al. Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based antico- agulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). Am J Cardiol. 2009;104:1285 91. 740. Jolicoeur EM, Ohman EM, Honeycutt E, et al. Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. Am J Cardiol. 2009;104:292 7. 741. Baumann BM, Perrone J, Hornig SE, et al. Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes. Acad Emerg Med. 2000;7:878 85. 742. Honderick T, Williams D, Seaberg D, et al. A prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes. Am J Emerg Med. 2003;21:39 42. 743. Hollander JE. Cocaine intoxication and hypertension. Ann Emerg Med. 2008;51:S18 20. 744. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation. 2010;122:2558 69. 745. Finkel JB, Marhefka GD. Rethinking cocaine-associated chest pain and acute coronary syndromes. Mayo Clin Proc. 2011;86:1198 207. 746.


Rethinking cocaine-associated chest pain and acute coronary syndromes. Mayo Clin Proc. 2011;86:1198 207. 746. Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine- induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 1990;112:897 903. 747. Dattilo PB, Hailpern SM, Fearon K, et al. Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use. Ann Emerg Med. 2008;51:117 25. 748. Rangel C, Shu RG, Lazar LD, et al. Beta-blockers for chest pain associ- ated with recent cocaine use. Arch Intern Med. 2010;170:874 9. 749. Diercks DB, Kirk JD, Turnipseed SD, et al. Evaluation of patients with methamphetamine- and cocaine-related chest pain in a chest pain obser- vation unit. Crit Pathw Cardiol. 2007;6:161 4. 750. Watts DJ, McCollester L. Methamphetamine-induced myocardial infarc- tion with elevated troponin I. Am J Emerg Med. 2006;24:132 4. 751. Chen JP. Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coro- nary microvascular spasm. J Invasive Cardiol. 2007;19:E89 92. 752. Westover AN, Nakonezny PA, Haley RW. Acute myocardial infarc- tion in young adults who abuse amphetamines. Drug Alcohol Depend. 2008;96:49 56. 753. Parodi O, Maseri A, Simonetti I. Management of unstable angina at rest by verapamil. A double-blind cross-over study in coronary care unit. Br Heart J 1979; 41:167 74. 754. Chahine RA, Feldman RL, Giles TD, et al. Randomized placebo-con- trolled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group. J Am Coll Cardiol. 1993;21:1365 70. 755. Lombardi M, Morales MA, Michelassi C, et al. Efficacy of isosorbide- 5-mononitrate versus nifedipine in preventing spontaneous and ergonovine- induced myocardial ischaemia. A double-blind, placebo-controlled study. Eur Heart J. 1993;14:845 51. 756. Fukumoto Y, Yasuda S, Ito A, et al. Prognostic effects of benidipine in patients with vasospastic angina: comparison with diltiazem and amlo- dipine. J Cardiovasc Pharmacol. 2008;51:253 7.


Prognostic effects of benidipine in patients with vasospastic angina: comparison with diltiazem and amlo- dipine. J Cardiovasc Pharmacol. 2008;51:253 7. 757. Kimura E, Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation. 1981;63:844 8. 758. Kugiyama K, Ohgushi M, Sugiyama S, et al. Supersensitive dilator response to nitroglycerin but not to atrial natriuretic peptide in spastic cor- onary arteries in coronary spastic angina. Am J Cardiol. 1997;79:606 10. 759. Tani S, Nagao K, Anazawa T, et al. Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot study. J Cardiovasc Pharmacol. 2008;52:28 34. 760. Yasue H, Mizuno Y, Harada E, et al. Effects of a 3-hydroxy-3-meth- ylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol. 2008;51:1742 8. 761. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coro- nary spasm. Circulation. 1993;87:76 9. 762. Nobuyoshi M, Abe M, Nosaka H, et al. Statistical analysis of clinical risk factors for coronary artery spasm: identification of the most important determinant. Am Heart J. 1992;124:32 8. 763. Yamagishi M, Ito K, Tsutsui H, et al. Lesion severity and hypercholester- olemia determine long-term prognosis of vasospastic angina treated with calcium channel antagonists. Circ J. 2003;67:1029 35. 764. Koizumi T,Yokoyama M, Namikawa S, et al. Location of focal vasospasm provoked by ergonovine maleate within coronary arteries in patients with vasospastic angina pectoris. Am J Cardiol. 2006;97:1322 5. 765. Ong P, Athanasiadis A, Hill S, et al. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol. 2008;52:523 7. 766. Cheng CW,Yang NI, Lin KJ, et al.


2008;52:523 7. 766. Cheng CW,Yang NI, Lin KJ, et al. Role of coronary spasm for a positive noninvasive stress test result in angina pectoris patients without hemo- dynamically significant coronary artery disease. Am J Med Sci. 2008; 335:354 62. 767. Wakabayashi K, Suzuki H, Honda Y, et al. Provoked coronary spasm predicts adverse outcome in patients with acute myocardial infarction: a novel predictor of prognosis after acute myocardial infarction. J Am Coll Cardiol. 2008;52:518 22. 768. OzakiY, Keane D, Serruys PW. Fluctuation of spastic location in patients with vasospastic angina: a quantitative angiographic study. J Am Coll Cardiol. 1995;26:1606 14. 769. Kusama Y, Kodani E, Nakagomi A, et al. Variant angina and coronary artery spasm: the clinical spectrum, pathophysiology, and management. J Nippon Med Sch. 2011;78:4 12. 770. Ogawa H, Yasue H, Oshima S, et al. Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation. 1989;80:1617 26. 771. Stern S, Bayes de Luna A. Coronary artery spasm: a 2009 update. Circulation. 2009;119:2531 4. 772. Kim PJ, Seung KB, Kim DB, et al. Clinical and angiographic characteris- tics of acute myocardial infarction caused by vasospastic angina without organic coronary heart disease. Circ J. 2007;71:1383 6. 773. Herrmann J, Kaski J, Lerman A. Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur Heart J. 2012;33:2771 82. 774. Cannon ROI, Epstein SE. Microvascular angina as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol. 1988;61:1338 43. 775. Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women s Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109:2993 9. 776. Doyle M, Weinberg N, Pohost GM, et al.


2004;109:2993 9. 776. Doyle M, Weinberg N, Pohost GM, et al. Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI- sponsored WISE (Women s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Imaging. 2010;3:1030 6. 777. Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). Circulation. 2004;109:568 72. 778. Reynolds HR, Srichai MB, Iqbal SN, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation. 2011;124:1414 25. 779. Lanza GA, Sestito A, Sgueglia GA, et al. Current clinical features, diag- nostic assessment and prognostic determinants of patients with variant angina. Int J Cardiol. 2007;118:41 7. 780. Tweet MS, Hayes SN, Pitta SR, et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation. 2012;126:579 88. 781. Assomull RG, Lyne JC, Keenan N, et al. The role of cardiovascular mag- netic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J. 2007;28:1242 9. 782. Christiansen JP, Edwards C, Sinclair T, et al. Detection of myocar- dial scar by contrast-enhanced cardiac magnetic resonance imaging in patients with troponin-positive chest pain and minimal angiographic coronary artery disease. Am J Cardiol. 2006;97:768 71. 783. Martinez MW, Babuin L, Syed IS, et al. Myocardial infarction with nor- mal coronary arteries: a role for MRI? Clin Chem. 2007;53:995 6. 784. Rosen SD, Uren NG, Kaski JC, et al. Coronary A vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation. 1994;90:50 60. 785. Bugiardini R, Bairey Merz CN. Angina with normal coronary arteries: a changing philosophy. JAMA. 2005;293:477 84. 786. Kaski JC, Rosano GM, Collins P, et al. Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study.


Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol. 1995;25:807 14. 787. Ong P, Athanasiadis A, Borgulya G, et al. 3-year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syn- drome) study follow-up. J Am Coll Cardiol. 2011;57:147 52. 788. Cannon RO III, Watson RM, Rosing DR, et al. Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve. Am J Cardiol. 1985;56:242 6. 789. Bugiardini R, Borghi A, Biagetti L, et al. Comparison of verapamil ver- sus propranolol therapy in syndrome X. Am J Cardiol. 1989;63:286 90. 790. Maseri A. Ischemic Heart Disease: A Rational Basis for Clinical Practice and Clinical Research. New York, NY: Churchill Livingstone, 1995. 791. Lerman A, Burnett JC Jr., Higano ST, et al. Long-term L-arginine sup- plementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97:2123 8. 792. Rosano GM, Peters NS, Lefroy D, et al. 17-beta-Estradiol therapy less- ens angina in postmenopausal women with syndrome X. J Am Coll Cardiol. 1996;28: 1500 5. 793. Mosca L. Cardiology patient page. Heart disease prevention in women. American Heart Association. Circulation. 2004;109:e158 60. tion: aggressive vs. conservative therapy. J Invasive Cardiol. 2010;22:222 8. 795. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takot-subo) cardiomyopathy. JAMA. 2011;306:277 86. 796. Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Circulation. 2008;118:397 409. 797. Eitel I, Behrendt F, Schindler K, et al. Differential diagnosis of suspected apical ballooning syndrome using contrast-enhanced magnetic resonance imaging. Eur Heart J. 2008;29:2651 9. 798. Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy.


Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010;55:333 41. 799. Dote K, Sato H, Tateishi H, et al. [Myocardial stunning due to simul- taneous multivessel coronary spasms: a review of 5 cases]. J Cardiol. 1991;21:203 14. Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e413 800. Sharkey SW, Lesser JR, Zenovich AG, et al. Acute and reversible car- diomyopathy provoked by stress in women from the United States. Circulation. 2005;111:472 9. 801. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako- Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarc- tion. Am Heart J. 2008;155:408 17. 802. Akashi YJ, Goldstein DS, Barbaro G, et al. Takotsubo cardiomyopathy: a newformofacute,reversibleheartfailure.Circulation.2008;118:2754 62. 803. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352:539 48. 804. Elesber AA, Prasad A, Bybee KA, et al. Transient cardiac apical balloon- ing syndrome: prevalence and clinical implications of right ventricular involvement. J Am Coll Cardiol. 2006;47:1082 3. 805. Elesber AA, Prasad A, Lennon RJ, et al. Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol. 2007;50:448 52. 806. Ito K, Sugihara H, Katoh S, et al. Assessment of Takotsubo (ampulla) car- diomyopathy using 99mTc-tetrofosmin myocardial SPECT comparison with acute coronary syndrome. Ann Nucl Med. 2003;17:115 22. 807. Choy B, Hansen E, Moss AJ, et al. Relation of body mass index to sud- den cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction. Am J Cardiol. 2010;105:581 6. 808. Mahaffey KW, Tonev ST, Spinler SA, et al. Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol. 2010;139:123 33. 809.


Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol. 2010;139:123 33. 809. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled- release, phentermine plus topiramate combination on weight and asso- ciated comorbidities in overweight and obese adults (CONQUER): a randomised,placebo-controlled,phase3trial.Lancet.2011;377:1341 52. 810. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-con- trolled, phase 3 extension study. Am J Clin Nutr. 2012;95:297 308. 811. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067 77. 812. Busetto L, De SF, Pigozzo S, et al. Long-term cardiovascular risk and coronary events in morbidly obese patients treated with laparoscopic gas- tric banding. Surg Obes Relat Dis. 2013. 813. Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231. 814. Ozturk B, Tacoy G, Coskun U, et al. Gemcitabine-induced acute coro- nary syndrome: a case report. Med Princ Pract. 2009;18:76 80. 815. Criscitiello C, Metzger-Filho O, Saini KS, et al. Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res. 2012;14:209. 816. Chalubinski M, Wojdan K, Dorantowicz R, et al. Comprehensive insight into immune regulatory mechanisms and vascular wall determinants of atherogenesis - emerging perspectives of immunomodulation. Arch Med Sci. 2013;9:159 65. 817. American Heart Association. Get With the Guidelines. 2009. Available at: http://www.heart.org/HEARTORG/HealthcareResearch/ GetWithThe GuidelinesHFStroke/Get-With-The-Guidelines HFStroke_ UCM_001099_SubHomePage.jsp. Accessed August 28, 2014. 818. ASSENT-4 PCI Investigators.


Available at: http://www.heart.org/HEARTORG/HealthcareResearch/ GetWithThe GuidelinesHFStroke/Get-With-The-Guidelines HFStroke_ UCM_001099_SubHomePage.jsp. Accessed August 28, 2014. 818. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment eleva- tion acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569 78. 819. Bonow RO, Masoudi FA, Rumsfeld JS, et al. ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2008;52:2113 7. 820. Henry TD, Sharkey SW, Burke MN, et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation. 2008;118:2662 6. 821. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST- elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation. 2008;118:2596 648. 822. Le May MR, So DY, Dionne R, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2008;358:231 40. 823. National Cardiovascular Data Registry. Action Registry GWTG. 2009. Available at: http://www.ncdr.com/webncdr/ACTION/Default.aspx. Accessed June 10, 2009. 824. QualityNet.com. Measure Comparison (Inpatient Hospital Quality Measures). 2009. Available at: http://www.qualitynet.org/dcs/Conte cid=1138900297065. Accessed June 10, 2009. 825. The Joint Commission. Acute Myocardial Infarction Core Measure Set. 2009. Available at: http://www.jointcommission.org/core_measure_sets. aspx. Accessed August 28, 2014. 826. McAlister FA, Lawson FM, Teo KK, et al. A systematic review of ran- domized trials of disease management programs in heart failure. Am J Med. 2001;110:378 84. 827. Coleman K, Austin BT, Brach C, et al. Evidence on the chronic care model in the new millennium. Health Aff (Millwood). 2009;28:75 85.


Evidence on the chronic care model in the new millennium. Health Aff (Millwood). 2009;28:75 85. KEY WORDS: AHA Scientific Statements acute coronary syndrome angina, unstable antiplatelet agents coronary artery bypass graft electrocardiography ischemia myocardial infarction percutaneous coronary intervention troponin Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2014 AHA/ACC Guideline for the Management of Patients With Non-St-Elevation Acute Coronary Syndromes Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Ezra A. Amsterdam (Chair) University of California (Davis) Medical Center, Division of Cardiology Professor None None None None None None None Nanette K. Wenger (Vice Chair) Emory University, School of Medicine Professor of Medicine (Cardiology) Abbott Amgen AstraZeneca Gilead Sciences Janssen Pharmaceuticals Medtronic Merck Pfizer None None Abbott Eli Lilly Gilead Sciences Merck Pfizer None None All sections and 8. Ralph G. Brindis University of California, San Francisco Department of Medicine and the Phillip R. Lee Institute for Health Policy Studies Clinical Professor of Medicine None Volcano None None None None None Donald E. Casey, Jr Atlantic Health Vice President of Health and Chief Medical Officer None None None None None None None Theodore G. Ganiats University of California, San Diego School of Medicine Executive Director of Health Services Research Center None None None None None None None David R. Holmes, Jr Mayo Clinic Consultant, Cardiovascular Diseases None None None None None None None Allan S. Jaffe Mayo Clinic, Cardiovascular Division Professor of Medicine Abbott Alere Amgen Beckman- Coulter Critical Diagnostics ET Healthcare Ortho Clinical Diagnostic Radiometer Roche Thermo-Fishert Trinity None None None None None All sections 7.6, and 8.


Ralph G. Brindis University of California, San Francisco Department of Medicine and the Phillip R. Lee Institute for Health Policy Studies Clinical Professor of Medicine None Volcano None None None None None Donald E. Casey, Jr Atlantic Health Vice President of Health and Chief Medical Officer None None None None None None None Theodore G. Ganiats University of California, San Diego School of Medicine Executive Director of Health Services Research Center None None None None None None None David R. Holmes, Jr Mayo Clinic Consultant, Cardiovascular Diseases None None None None None None None Allan S. Jaffe Mayo Clinic, Cardiovascular Division Professor of Medicine Abbott Alere Amgen Beckman- Coulter Critical Diagnostics ET Healthcare Ortho Clinical Diagnostic Radiometer Roche Thermo-Fishert Trinity None None None None None All sections 7.6, and 8. Hani Jneid Baylor College of Medicine The Michael E. DeBakey VA Medical Center Assistant Professor of Medicine None None None None None None None (Continued) Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e415 Rosemary F. Kelly University of Minnesota Professor of Surgery; VA Medical Center Chief, Cardiothoracic Surgery None None None None None None None Michael C. Kontos Virginia Commonwealth University, Pauley Heart Center Medical Director, Coronary Intensive Care Unit, and Associate Professor, Internal Medicine Astellas General Electric Ikaria Prevencio Sanofi-aventis Wellpoint/Anthem Astellas AstraZeneca None None Astellas Eli Lilly Merck Novartis None All sections Glenn N. Levine Baylor College of Medicine Professor of Medicine; Director, Cardiac Care Unit None None None None None None None Philip R. Liebson Rush University Medical Center McMullan-Eybel Chair of Excellence in Clinical Cardiology and Professor of Medicine and Preventive Medicine None None None None None None None Debabrata Mukherjee Texas Tech University Health Sciences Center Chief, Cardiovascular Medicine None None None None None None None Eric D. Peterson Duke University Medical Center Fred Cobb, MD, Distinguished Professor of Medicine; Duke Clinical Research Institute Director Boehringer Ingelheim Genentech Janssen Pharmaceuticals Johnson & Johnson Merck None None Eli Lilly Johnson & Johnson Janssen Pharmaceuticals DCRI has numerous grants and contracts sponsored by industry that are relevant to the content of this CPG.


Hani Jneid Baylor College of Medicine The Michael E. DeBakey VA Medical Center Assistant Professor of Medicine None None None None None None None (Continued) Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e415 Rosemary F. Kelly University of Minnesota Professor of Surgery; VA Medical Center Chief, Cardiothoracic Surgery None None None None None None None Michael C. Kontos Virginia Commonwealth University, Pauley Heart Center Medical Director, Coronary Intensive Care Unit, and Associate Professor, Internal Medicine Astellas General Electric Ikaria Prevencio Sanofi-aventis Wellpoint/Anthem Astellas AstraZeneca None None Astellas Eli Lilly Merck Novartis None All sections Glenn N. Levine Baylor College of Medicine Professor of Medicine; Director, Cardiac Care Unit None None None None None None None Philip R. Liebson Rush University Medical Center McMullan-Eybel Chair of Excellence in Clinical Cardiology and Professor of Medicine and Preventive Medicine None None None None None None None Debabrata Mukherjee Texas Tech University Health Sciences Center Chief, Cardiovascular Medicine None None None None None None None Eric D. Peterson Duke University Medical Center Fred Cobb, MD, Distinguished Professor of Medicine; Duke Clinical Research Institute Director Boehringer Ingelheim Genentech Janssen Pharmaceuticals Johnson & Johnson Merck None None Eli Lilly Johnson & Johnson Janssen Pharmaceuticals DCRI has numerous grants and contracts sponsored by industry that are relevant to the content of this CPG. Dr. Peterson participated in discussions but recused himself from writing or voting, in accordance with ACC/AHA policy. See comprehensive RWI table for a complete list of companies pertaining to this organization. None All sections Appendix 1.


See comprehensive RWI table for a complete list of companies pertaining to this organization. None All sections Appendix 1. Continued Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* (Continued) Marc S. Sabatine Brigham and Women s Hospital, Chairman TIMI Study Group, Division of Cardiovascular Medicine; Harvard Medical School Professor of Medicine Amgen AstraZeneca Bristol-Myers Squibb Merck Pfizer Sanofi-aventis None None Abbott Laboratories Amgen AstraZeneca Bristol-Myers Squibb Critical Diagnostics Daiichi-Sankyo Genzyme GlaxoSmithKline Nanosphere Roche Diagnostics Sanofi-aventis Takeda AstraZeneca Daiichi-Sankyo Gilead Johnson & Johnson BRAHMS Proventys Siemens Singulex None All sections except and 8. Richard W. Smalling University of Texas, Health Science Center at Houston Professor and Director of Interventional Cardiovascular Medicine; James D. Woods Distinguished Chair in Cardiovascular Medicine Gilead Maquet None None Cordis E-valve Abbott Vascular Edwards Lifesciences Gilead Maquet Datascope Cordis E-valve None All sections except 7.8, and 8. Susan J. Zieman National Institute on Aging/NIH, Geriatrics Branch, Division of Geriatrics and Clinical Gerontology Medical Officer None None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the GWC during the document development process. The table does not necessarily reflect relationships with industry at the time of publication.


The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; ore) the person or a member of the person s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. *Writing members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Section numbers pertain to those in the full-text CPG. Significant relationship. No financial benefit. ACC indicates American College of Cardiology, AHA, American Heart Association, BMS, Bristol-Myers Squibb; CPG, clinical practice guideline; DCRI, Duke Clinical Research Institute; NIH, National Institutes of Health; NYU, New York University; RWI, relationships with industry and other entities; TIMI, Thrombolysis In Myocardial Infarction; and VA, Veterans Affairs. Appendix 1.


ACC indicates American College of Cardiology, AHA, American Heart Association, BMS, Bristol-Myers Squibb; CPG, clinical practice guideline; DCRI, Duke Clinical Research Institute; NIH, National Institutes of Health; NYU, New York University; RWI, relationships with industry and other entities; TIMI, Thrombolysis In Myocardial Infarction; and VA, Veterans Affairs. Appendix 1. Continued Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e417 Appendix 2.


Continued Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e417 Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Deepak L. Bhatt Official Reviewer AHA VA Boston Healthcare System Professor of Medicine, Harvard Medical School; Chief of Cardiology BMS/Pfizer DCRI (BMS/ Pfizer) DCRI (Eli Lilly) Eli Lilly None None AstraZeneca* Bristol-Myers Squibb* Ethicon* The Medicines Company Medtronic* Sanofi-aventis* Takeda Medscape Cardiology (Advisory Board) WebMD (Steering Committee) None John E. Brush, Jr Official Reviewer ACC Board of Trustees Eastern Virginia Medical School Professor of Medicine, Chief of Cardiology None None None None None None E. Magnus Ohman Official Reviewer ACC/ AHA Task Force on Practice Guidelines Duke Medicine Professor of Medicine AstraZeneca Bristol-Myers Squibb Gilead* Janssen Pharmaceuticals* The Medicines Company Merck Pozen Roche Sanofi-aventis Gilead* Janssen Pharmaceuticals None Daiichi-Sankyo* Eli Lilly* Gilead* None None John F. Robb Official Reviewer ACC Board of Governors Dartmouth-Hitchcock Medical Center Director, Interventional Cardiology and Cardiac Catheterization Laboratories None None None None None Defendant, adverse drug reaction, Sarah A. Spinier Official Reviewer AHA Philadelphia College of Pharmacy, University of the Sciences in Philadelphia Professor of Clinical Pharmacy Bristol-Myers Squibb Daiichi-Sankyo Janssen Pharmaceuticals Merck None None None None Plaintiff, clopidogrel, Gorav Ailawadi Organizational Reviewer STS University of Virginia Health System Thoracic and Cardiovascular Surgery Abbott Atricure None None None None None Srihari S. Naidu Organizational Reviewer SCAI Winthrop University Hospital Director, Cardiac Catheterization Laboratory None None None None None None Robert L. Rich, Jr Organizational Reviewer AAFP Bladen Medical Associates Family Physician None None None None None None Mouaz H. Al-Mallah Content Reviewer ACC Prevention of Cardiovascular Disease Committee King Abdul-Aziz Cardiac Center Associate Professor of Medicine None None None None None None (Continued) John A. Ambrose Content Reviewer University of California San Francisco Fresno Department of Medicine Professor of Medicine; Chief of Cardiology; Program Director, Cardiology Fellowship None None None None None None Giuseppe Ambrosio Content Reviewer-ACC Prevention of Cardiovascular Disease Committee Hospital of University of Perugia School of Medicine Medical Director, Division of Cardiology Bayer* The Medicines Company Merck Schering-Plough Sanofi-aventis Merck Schering-Plough Pfizer None None None None H. Vernon Anderson Content Reviewer University of Texas Professor of Medicine, Cardiology Division None None None None Eli Lilly None Jeffrey L. Anderson Content Reviewer ACC/ AHA Task Force on Practice Guidelines Intermountain Medical Center Associate Chief of Cardiology Sanofi-aventis None None GlaxoSmithKline Harvard (DSMB)-TIMI None None Fred S. Apple Content Reviewer University of Minnesota School of Medicine, Hennepin County Medical Center Professor, Laboratory Medicine and Pathology Abbott Diagnostics Alere Beckman Coulter T2 Biosystems None None Abbott* Alere/Biosite* Biomerieux* Ortho-Clinical Diagnostics-PI Ortho-Clinical Diagnostics* Radiometer* Roche Laboratories* Siemens* Abbott Diagnostics-PI Alere-PI None Emmanouil S. Brilakis Content Reviewer ACC Interventional Section Leadership Council UT Southwestern Medical School Director, Cardiac Catheterization Laboratory, VA North Texas Healthcare System Bridgepoint Medical/Boston Scientific* Janssen Pharmaceuticals Sanofi-aventis None None None Abbott Vascular AstraZeneca Cordis* Daiichi-Sankyo* The Medicines Company Medtronic* None Matthew J. Budoff Content Reviewer ACC Cardiovascular Imaging Section Leadership Council Los Angeles Biomedical Research Institute Program Director, Division of Cardiology and Professor of Medicine None AstraZeneca None General Electric* None P laintiff, cardiac treatment, James A. Burke Content Reviewer ACC Interventional Section Leadership Council Lehigh Valley Health Network Interventional Cardiologist None None None None None None Appendix 2.


Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness (Continued) Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e419 Robert H. Christenson Content Reviewer AACC University of Maryland School of Medicine Professor of Pathology; Professor of Medical and Research Technology; Director, Rapid Response Laboratory BG Medicine Critical Diagnostics Siemens Medical Diagnostics None None The Medicines Company AACC (President) Roche Diagnostics (University of Maryland School of Medicine)* None Joaquin E. Cigarroa Content Reviewer ACC Interventional Section Leadership Council Oregon Health and Science University Associate Professor of Medicine None None None None Catheterization and Cardiovascular Intervention (Editorial Board) None Marco A. Costa Content Reviewer ACC Cardiovascular Imaging Section Leadership Council University Hospital for Cleveland Cardiologist Abbott Vascular* Boston Scientific Medtronic None None Abbott Vascular* Boston Scientific* Cordis* IDEV Technology The Medicines Company Medtronic* Micell* OrbusNeicht Abbott Cordis Medtronic None Prakash C. Deedwania Content Reviewer ACC Prevention of Cardiovascular Disease Committee University of California San Francisco Chief of Cardiology Amgen Pfizer Pfizer Takeda Pharmaceuticals None None None None James A. de Lemos Content Reviewer UT Southwestern Medical School Associate Professor of Medicine; Director, Coronary Care Unit and Cardiology Fellowship Diadexus Janssen Pharmaceuticals AstraZeneca None Abbott Diagnostics Daiichi-Sankyo None Burl R. Don Content Reviewer University of California Davis Professor of Medicine; Director of Clinical Nephrology None None None None None None Lee A. Fleisher Content Reviewer University of Pennsylvania Department of Anesthesiology Professor of Anesthesiology None None None None None None Mary G. George Content Reviewer HHS Centers for Disease Control and Prevention Senior Medical Officer, Division for Heart Disease and Stroke Prevention None None None None None None Linda D. Gillam Content Reviewer ACC Cardiovascular Imaging Section Leadership Council Morristown Medical Center Professor of Cardiology; Vice Chair, Cardiovascular Medicine None None None None None None (Continued) Appendix 2.


Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Robert A. Guyton Content Reviewer ACC/ AH A Task Force on Practice Guidelines Emory Clinic Professor and Chief, Division of Cardiothoracic Surgery Medtronic None None None None None Joerg Herrmann Content Reviewer ACC Interventional Section Leadership Council Mayo Medical School- Internal Medicine and Cardiovascular Disease None None None None None None Judith S. Hochman Content Reviewer ACC/ AHA Task Force on Practice Guidelines New York University School of Medicine, Division of Cardiology Clinical Chief of Cardiology GlaxoSmithKline Janssen Pharmaceuticals None None None None None Yuling Hong Content Reviewer HHS Centers for Disease Control and Prevention Associate Director None None None None None None Lloyd W. Klein Content Reviewer ACC Interventional Section Leadership Council Rush Medical College-Professor of Medicine None None None None None None Frederick G. Kushner Content Reviewer Tulane University School of Medicine Clinical Professor of Medicine; Heart Clinic of Louisiana Medical Director None None None None None None Ehtisham Mahmud Content Reviewer ACC Interventional Section Leadership Council University of California, San Diego Professor of Medicine/Cardiology, Chief of Cardiovascular Medicine; Director, Interventional Cardiology and Cardiovascular Catheterization Laboratory Abiomed Cordist Eli Lilly* Gilead Johnson & Johnson Medtronic Eli Lilly* Medtronic None Abbott Vascular* Accumetrics* Merck Schering-Plough Boston Scientific* Gilead* The Medicines Company Sanofi-aventis* None None Carlos Mart nez- S nchez Content Reviewer AIG Cardiology Society of Mexico President None None None AstraZenecat Eli Lilly Sanofi-aventis None None L. Kristen Newby Content Reviewer Duke University Medical Center Associate Professor of Clinical Medicine Johnson & Johnson Daiichi-Sankyo None None Amylin AstraZeneca Bristol-Myers Squibb* Eli Lilly GlaxoSmithKline Merck* None None Patrick T. O Gara Content Reviewer Brigham and Women s Hospital Professor of Medicine, Harvard Medical School; Director, Clinical Cardiology None None None None None None Appendix 2.


Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness (Continued) Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e421 Narith Ou Content Reviewer Mayo Clinic Pharmacotherapy Coordinator, Pharmacy Services None None None None None None Gurusher S. Panjrath Content Reviewer ACC Heart Failure and Transplant Section Leadership Council George Washington Medical Faculty Associates Assistant Professor of Medicine; Director of Heart Failure and Mechanical Support Program None None None None None None Rajan Patel Content Reviewer ACC Cardiovascular Imaging Section Leadership Council Ochsner Clinic Foundation Interventional Cardiologist None None None None None None Carl J. Pepine Content Reviewer Shands Hospital at University of Florida Professor and Chief, Division of Cardiovascular Medicine Lilly/Cleveland Clinic (DSMB) None None AstraZeneca* Gilead Sciences* Park-Davis* Pfizer* Sanofi-aventis* None None Sunil V. Rao Content Reviewer ACC Interventional Section Leadership Council Duke University Medical Center- Associate Professor of Medicine AstraZeneca Daiichi-Sankyo Eli Lilly Terumo Medical The Medicines Company None None Sanofi-aventis Abbott Vascular None Pasala S. Ravichandran Content Reviewer ACC Surgeons Scientific Council Oregon Health and Science University Associate Professor None None None None None None Michael W. Rich Content Reviewer Washington University School of Medicine Professor of Medicine None None None None None None Frank W. Sellke Content Reviewer- ACC/AHA Task Force on Practice Guidelines Brown Medical School, Rhode Island Hospital Professor; Chief of Cardiothoracic Surgery None None None None None None Alan Wu Content Reviewer AACC San Francisco General Hospital and Trauma Center Chief, Clinical Chemistry Laboratory Abbott Singulex None None None None None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant to this document. It does not necessarily reflect relationships with industry at the time of publication.


It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. *Significant relationship. No financial benefit.


According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. *Significant relationship. No financial benefit. AAAHC indicates Accreditation Association for Ambulatory Health Care; AACC, American Association for Clinical Chemistry; AAFP, American Academy of Family Physicians; AHA, American Heart Association; AIG, Association of International Governors; BMS, Bristol-Myers Squibb; DCRI, Duke Clinical Research Institute; DSMB, data safety monitoring board; HHS, Health and Human Services; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; SCAI, Society for Cardiovascular Angiography and Interventions; STS, Society of Thoracic Surgeons; TIMI, Thrombolysis In Myocardial Infarction; and VA, Veterans Affairs. Appendix 2. Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Appendix 3.


Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Appendix 3. Abbreviations ACE = angiotensin-converting enzyme ACS = acute coronary syndrome AF = atrial fibrillation AMI = acute myocardial infarction BP = blood pressure CABG = coronary artery bypass graft CAD = coronary artery disease CKD = chronic kidney disease CK-MB = creatine kinase myocardial isoenzyme COX = cyclooxygenase CPG = clinical practice guideline CrCl = creatinine clearance CT = computed tomography DAPT = dual antiplatelet therapy DES = drug-eluting stent ECG = electrocardiogram ED = emergency department GDMT = guideline-directed medical therapy GP = glycoprotein GFR = glomerular filtration rate GWC = guideline writing committee HF = heart failure IABP = intra-aortic balloon pump IV = intravenous LMWH = low-molecular-weight heparin LV = left ventricular LVEF = left ventricular ejection fraction MACE = major adverse cardiac event MI = myocardial infarction = myocardial oxygen consumption NSAID = nonsteroidal anti-inflammatory drug NSTE-ACS = non-ST-elevation acute coronary syndromes NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention RCT = randomized controlled trial SC = subcutaneous STEMI = ST-elevation myocardial infarction UA = unstable angina UFH = unfractionated heparin VF = ventricular fibrillation VT = ventricular tachycardia Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e423 Appendix 4. Additional Tables Table A. Universal Classification of MI Type 1: Spontaneous MI Spontaneous MI related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in 1 of the coronary arteries leading to decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis. The patient may have underlying severe CAD, but on occasion nonobstructive or no CAD.


The patient may have underlying severe CAD, but on occasion nonobstructive or no CAD. Type 2: MI secondary to ischemic imbalance In instances of myocardial injury with necrosis where a condition other than CAD contributes to an imbalance between MVO2 , eg, coronary endothelial dysfunction, coronary artery spasm, coronary embolism, tachy-/bradyarrhythmias, anemia, respiratory failure, hypotension, and hypertension with or without LVH. Type 3: MI resulting in death when biomarker values are unavailable Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic electrocardiographic changes or new LBBB, but death occurred before blood samples could be obtained, before cardiac biomarker could rise, or in rare cases where blood was not collected for cardiac biomarker testing. Type 4a: MI related to PCI MI associated with PCI is arbitrarily defined by elevation of cTn values >5 99th percentile URL in patients with normal baseline values (<99th percentile URL) or a rise of cTn values >20% if baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial ischemia, (ii) new ischemic electrocardiographic changes or new LBBB, (iii) angiographic loss of patency of a major coronary artery or a side branch or persistent slow or no flow or embolization, or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality is required. Type 4b: MI related to stent thrombosis MI associated with stent thrombosis is detected by coronary angiography or autopsy in the setting of myocardial ischemia and with a rise and/or fall of cardiac biomarker values with 1 value above the 99th percentile URL. Type 5: MI related to CABG MI associated with CABG is arbitrarily defined by elevation of cardiac biomarker values >10 99th percentile URL in patients with normal baseline cTn values (<99th percentile URL).


Type 5: MI related to CABG MI associated with CABG is arbitrarily defined by elevation of cardiac biomarker values >10 99th percentile URL in patients with normal baseline cTn values (<99th percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographically documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. CABG indicates coronary artery bypass graft; CAD, coronary artery disease; cTn, cardiac troponin; LBBB, left bundle-branch block; LVH, left ventricular hypertrophy; MI, myocardial infarction; MVO2 , myocardial oxygen consumption; PCI, percutaneous coronary intervention; and URL, upper reference limit.


CABG indicates coronary artery bypass graft; CAD, coronary artery disease; cTn, cardiac troponin; LBBB, left bundle-branch block; LVH, left ventricular hypertrophy; MI, myocardial infarction; MVO2 , myocardial oxygen consumption; PCI, percutaneous coronary intervention; and URL, upper reference limit. Modified from Thygesen et al.21 Table B. Pharmacological Therapy in Older Patients With NSTE-ACS Age-Related Pharmacological Change Clinical Effect Dose-Adjustment Recommendations Additional Precautions General principles In renal function (CrCl*): drug clearance, water/ electrolyte balance SCr unreliable measure of renal function in older adults Change in body composition Fat, lean body mass/total water GI absorption Levels renally cleared drug Risk high/low electrolyte levels Levels hydrophilic agents Levels lipophilic agents Longer time to reach steady- state lipophilic agents Calculate CrCl in all pts renal- dose accordingly Start at lowest recommended dose, titrate up slowly Avoid interacting drugs Consider doses in women, malnourished, hypovolemic Caution fall risk with BP agents and diuretics Monitor for ADR, especially delirium Frequent monitoring of renal function/electrolytes Minimize polypharmacy watch for drug-drug interactions ASA Hydrophilic; levels with total body water; age-related plasma concentration for similar dose Bleeding risk with age, dehydration, frailty, diuretics Maintenance=81 mg/d (lowest possible dose) Bleeding with NSAIDs, other AP, AC, AT; risk peptic ulcer with NSAIDs Nitrates Sensitivity Hypotensive response with baroreceptor response Lowest dose possible, especially if hypovolemic Risk OH, syncope, falls ACE inhibitors First-pass metabolism (some) with effect; enalapril effect May have effect May need dose Risk AKI and K+ and effect with NSAIDs; avoid K-sparing diuretics ARBs No significant age-related changes No age-related clinical changes None Risk AKI and K+ and effect with NSAIDs; avoid K-sparing diuretics Alpha blockers Sensitivity; BP with baroreceptor response BP; OH Avoid when possible Risk OH, falls, syncope, especially with loop diuretics Beta blockers Myocardial sensitivity ( postreceptor signaling), conduction system sensitivity Bradycardia/heart block; BP effect vs. younger pts May need dose with age Caution conduction system blocks (Continued) CCBs DHPs (amlodipine; nifedipine) Lipophilic; hepatic and overall clearance; fat storage; sinus node sensitivity; baroreceptor response to BP BP more than non DHP and with age; edema hypotension, bradycardia Initiate low dose, titrate cautiously Inhibits clopidogrel; risk OH, falls, syncope; most potent BP first 3 mo, then less Non-DHP (verapamil; diltiazem) Hepatic and overall clearance; less PR prolongation than DHP and with age; negative inotropy; SA node sensitivity and HR than DHP and with age; AV conduction with age; baroreceptor response to BP BP more with tage; edema; heart block; hypotension; bradycardia and bradyarrhythmias with age Initiate low dose, titrate cautiously Risk OH, falls, syncope; consider rhythm monitoring Diuretics Diuretic/natriuretic response, EC space, drug concentration if GFR; baroreceptor response to volume shifts Sensitivity; hypotension; risk hypokalemia/hypomagnesemia/ hyponatremia; diuretic effect with GFR; risk hypovolemia- thirst May need doses if GFR; may need dose if cotreating with NSAIDs Monitor Na+ , K+ levels; risk OH/falls; With NSAIDs: natriuretic and diuretic effect, K+ Heparins UFH Hydrophilic; concentration, especially if lean body mass or plasma proteins; levels with age Bleeding risk with age; more potent anticoagulation per dose with age; weight-based dosing but with precautions for shift in body composition Weight-based 60 U/kg loading dose + 12 U/kg/h INF.


Suggested max loading dose: 400 U and 900 U/h INF or 5000 U loading dose/1000 U/h if pt weight >100 kg Bleeding with ASA; bleeding risk with other AP, AT, and GP IIb/IIIa; vigilantly monitor aPTT LMWH Cleared renally; more predictable dose response than UFH; not dependent on plasma protein levels; levels with lean body mass; effect with age Bleeding risk with age and weight and renally dosed Enoxaparin: Weight-based 1 mg/kg SC q 12 h; CrCl* <30 mL/min avoid or 1 mg/kg SC q 24 h; CrCl Dalteparin: Use caution in older pts with low body weight or renal insufficiency Bleed with ASA Monitor anti-Xa; bleeding with GP IIb/IIIa with age Direct Thrombin Inhibitors Bivalirudin Cleared renally; more predictable dose response; not dependent on plasma protein levels Significantly less bleeding in older pts, even with renal dysfunction vs. UFH + GP IIb/IIIa with similar efficacy CrCl <30 mL/min: 1 mg/kg/h; CrCl: 30 to 60 mL/min less bleeding than UFH Less bleeding than GP IIb/IIIa inhibitor + heparin Fondaparinux Cleared renally Renal/weight adjust; less bleeding but similar efficacy vs. enoxaparin in older pts with NSTE-ACS, even with mild to moderate renal dysfunction Renal adjustment: CrCl over enoxaparin Bleeding vs. enoxaparin; good safety profile vs. UFH/LMWH Inhibitors Clopidogrel Lipophilic; HPR; metabolism; fat distribution; to steady state ( fat distribution/T ) Antiplatelet effect in some older pts Maintenance: 75 mg (no response to higher dose) Effect with proton pump inhibitors; if HPR may respond to prasugrel or ticagrelor Prasugrel l9% Active metabolite >75 y of age Bleeding risk Avoid in pts 75 y of age or if weight 60 kg; 10 mg in very high-risk pts N/A Ticagrelor None known N/A None Reversible GP IIb/IIIa Inhibitors Abciximab N/A Bleeding with age Not recommended N/A Bleeding risk without clinical benefit Table B.


Continued Age-Related Pharmacological Change Clinical Effect Dose-Adjustment Recommendations Additional Precautions (Continued) Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e425 GP IIb/IIIa Inhibitors (continued) Eptifibatide Weight/renally dosed Bleeding risk Weight-based: 180 mcg/kg loading dose + 2 mcg/kg/min INF; CrCl 50 mL/min: 1.0 mcg/kg/min INF Less benefit/more bleeding with age Tirofiban Weight/renally dosed Bleeding risk Weight-based: 12 mcg/kg loading dose + 0.14 mcg/kg/min INF; CrCl <30 mL/min: 6 mcg/kg loading dose + 0.05 mcg/kg/min INF In older pts with high bleeding risk, low-dose INF effective with bleeding Warfarin Sensitivity; 20% 40% clearance; protein binding; inhibition vitamin K-dependent clotting factors at same plasma levels with age Bleeding risk at lower INR; higher INR/dose with age risk GI bleeding Loading: 4 mg/d 4 d Maintain mean dose 0.4 mg/w/y of age Multiple drug interactions, frequency of monitoring; ASA potentiates effect New Oral AC N/A N/A Contraindicated if CrCl If pt taking when admitted, stop consider delaying angiogram/ PCI until effect wanes, switch to UFH/dalteparin/bivalirudin/ fondaparinux; AP and DAPT bleeding 2 post-ACS consider BMS and radial access. Avoid GP IIb/IIIa inhibitor if possible; thrombotic risk following discontinuation.


Avoid GP IIb/IIIa inhibitor if possible; thrombotic risk following discontinuation. Rivaroxaban 35% cleared renally; 65% hepatic (CYP3A4); levels in hepatic and/or renal dysfunction and age Bleeding risk; not reversible CrCl 15 49 mL/min: 15 mg QD; consider avoiding if CrCl 15 30 mL/min if bleeding risk; CrCl >50 mL/min: 20 mg QD Some drug interactions Dabigatran 80% cleared renally; plasma level with age, especially Bleeding risk; not reversible CrCl 15 30 mL/min: 75 mg BID with caution; CrCl 30 49 mL/min: 75 mg BID; CrCl >50 mL/min: 150 mg BID Monitor pt and renal function frequently; longest for effect to wane with CrCl; risk dyspepsia, GI bleeding Apixaban Hepatically cleared (minor CYP3A4); dose adjust if weight 60 kg; highly protein bound Bleeding risk; not reversible CrCl 15 29 mL/min: 2.5 mg BID or with 2 of the following: age 80 y/weight 60 kg/SCr 1.5 mg/ dL: SCr <1.5: 5 mg BID Risk abnormal liver function tests *CrCl should be calculated for all older pts because SCr level does not accurately reflect renal dysfunction: CrCl decreases with age 0.7 mL/min/y. These agents are not approved for NSTE-ACS but are included for management of pts with nonvalvular chronic atrial fibrillation.


These agents are not approved for NSTE-ACS but are included for management of pts with nonvalvular chronic atrial fibrillation. AC indicates anticoagulants; ACE, angiotensin-converting-enzyme; ACS, acute coronary syndromes; ADR, adverse drug reactions; AKI, acute kidney injury; AP, antiplatelets; aPTT, activated partial thromboplastin time; ARB, angiotensin receptor blocker; ASA, aspirin; AT, antithrombins; AV, atrioventricular; BID, twice daily; BMS, bare-metal stent; BP, blood pressure; CCBs, calcium channel blockers; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; DHP, dihydropyridine; EC, extracellular; GFR, glomerular filtration rate; GI, gastrointestinal; GP, glycoprotein; HPR, high platelet reactivity; HR, heart rate; INF, infusion; INR, international normalized ratio; K+ , potassium; LMWH, low-molecular-weight heparin; max, maximum; Mg, magnesium; N/A, not available; NSAIDs, nonsteroidal anti-inflammatory drugs; NSTE-ACS, non-ST-elevation acute coronary syndromes; OH, orthostatic hypotension; PCI, percutaneous coronary intervention; pts, patients; QD; once daily; SA, sinoatrial; SC, subcutaneous; SCr, serum creatinine; T , half-life; and UFH, unfractionated heparin. Table B.


AC indicates anticoagulants; ACE, angiotensin-converting-enzyme; ACS, acute coronary syndromes; ADR, adverse drug reactions; AKI, acute kidney injury; AP, antiplatelets; aPTT, activated partial thromboplastin time; ARB, angiotensin receptor blocker; ASA, aspirin; AT, antithrombins; AV, atrioventricular; BID, twice daily; BMS, bare-metal stent; BP, blood pressure; CCBs, calcium channel blockers; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; DHP, dihydropyridine; EC, extracellular; GFR, glomerular filtration rate; GI, gastrointestinal; GP, glycoprotein; HPR, high platelet reactivity; HR, heart rate; INF, infusion; INR, international normalized ratio; K+ , potassium; LMWH, low-molecular-weight heparin; max, maximum; Mg, magnesium; N/A, not available; NSAIDs, nonsteroidal anti-inflammatory drugs; NSTE-ACS, non-ST-elevation acute coronary syndromes; OH, orthostatic hypotension; PCI, percutaneous coronary intervention; pts, patients; QD; once daily; SA, sinoatrial; SC, subcutaneous; SCr, serum creatinine; T , half-life; and UFH, unfractionated heparin. Table B. Continued Age-Related Pharmacological Change Clinical Effect Dose-Adjustment Recommendations Additional Precautions Table C. Age-Related Physiological Changes: Clinical Impact in Older Patients With NSTE-ACS Age-Related Change Clinical Alteration Clinical Impact in NSTE-ACS Central arterial stiffness SBP/ DBP; LVH; diastolic function; coronary perfusion pressure; ischemia/infarct threshold for tachycardia/hypertension with and without coronary obstructive disease; PA pressure Risk end-organ damage (cerebrovascular accident, AKI); BP lability; reinfarction/ischemia; orthostatic hypotension; HF; pulmonary edema LV diastolic function LA size; early passive LV filling; late LV filling and LV EDP; PA pressure Risk AF; ( pulmonary edema/ CO), DOE; pulmonary edema with HR/ BP Response to beta-adrenergic stimulation HR/ inotropic responsiveness to stress; resting systolic LV function unchanged with age Hypotension, HF, HR response Conduction system changes Sinus node cells; AV conduction; LBBB; and RBBB Difficult to interpret electrocardiographic MI/ischemia; heart block; SSS; SVT, sensitivity to conduction system drugs Volume regulating hormones Na, K, and water regulation BP lability Altered electrolytes, sensitivity to fluid therapy/diuretics Renal changes GFR (0.8 mL/min/y), Na/K clearance, normal serum creatinine despite moderate to severe CKD, altered drug clearance; urine concentrating ability CrCl or eGFR must be calculated for drug dosing, sensitivity to contrast nephropathy, risk AKI Fat-muscle redistribution Third spacing of fluid, may alter drug storage; Vo2max May alter fluid/drug dosing, decreased CO; DOE; early fatigability Baroreceptor sensitivity BP lability Orthostatic hypotension, fall risk Clotting factor/platelet function/hemostasis Bleeding and clotting risk, sensitivity to anticoagulants/antithrombins Risk cerebrovascular accident/reinfarction/recurrent ischemia, bleeding, thrombosis, PE, DVT; may alter drug dosing/sensitivity; stent thrombosis AF indicates atrial fibrillation; AKI, acute kidney injury; AV, atrioventricular; BP, blood pressure; CKD, chronic kidney disease; CO, cardiac output; CrCl, creatinine clearance; DBP, diastolic blood pressure; DOE, dyspnea on exertion; DVT, deep vein thrombosis; EDP, end-diastolic pressure; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; HF, heart failure; HR, heart rate; K, potassium; LA, left atrium; LBBB, left bundle-branch block; LV, left ventricular; LVH, left ventricular hypertrophy; MI, myocardial infarction; NA, sodium; Na/K sodium and potassium clearance; NTSE-ACS, non ST-elevation acute coronary syndrome; PA, pulmonary artery; PE, pulmonary embolism; RBBB, right bundle-branch block, SBP, systolic blood pressure; SSS, sick sinus syndrome; SVT, supraventricular tachycardia; and Vo2max , maximum oxygen consumption.


Table D. FREEDOM Trial: Key Outcomes at 2 Years and 5 Years After Randomization Outcome P Value* PCI CABG PCI CABG Number (%) *P values were calculated with the log-rank test on the basis of all available follow-up data (ie, >5 y). The primary composite outcome was rate of death from any cause, MI, or stroke. P=0.006 in the as-treated (non-intention-to-treat) analysis. P=0.16 by the WaLd test of the Cox regression estimate for study-group assignment in 1712 patients after adjustment for average glucose Level after procedure. CABG indicates coronary artery bypass graft; FREEDOM, Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease; MI, myocardial infarction; and PCI, percutaneous coronary intervention. Modified with permission from Farkouh et al.616


BackgroundandPurpose Thepurposeoftheseguidelinesistoprovideanup-to-datecomprehensivesetofrecommendations in a single document for clinicians caring for adult patients with acute arterial ischemic stroke. The intended audiences are prehospital care providers, physicians, allied health professionals, and hospital administrators. These guidelines supersede the 2013 Acute Ischemic Stroke (AIS) Guidelines and are an update of the 2018 AIS Guidelines. Methods Members of the writing group were appointed by the American Heart Association (AHA) Stroke Council s Scientific Statements Oversight Committee, representing various areas of medical expertise. Members were not allowed to participate in discussions or to vote on topics relevant to their relations with industry. An update of the 2013 AIS Guidelines was originally published in January 2018. This guideline was approved by the AHA Science Advisory and Coordinating Committee and the AHA Executive Committee. In April 2018, a revision to these guidelines, deleting some recommendations, was published online by the AHA. The writing group was asked review the original document and revise if appropriate. In June 2018, the writing group submitted a document with minor changes and with inclusion of important newly published randomized controlled trials with >100 participants and clinical outcomes at least 90 days after AIS. The document was sent to 14 peer reviewers. The writing group evaluated the peer reviewers comments and revised TheAmerican HeartAssociation makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.


Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest. This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on September 12, 2019, and the American Heart Association Executive Committee on October 3, 2019. A copy of the document is available at https://professional.heart.org/statements by using either Search for Guidelines & Statements or the Browse by Topic area. To purchase additional reprints, call 843-216-2533 or email kelle. ramsay@wolterskluwer.com. The online-only Data Supplements are available with this article at https://www.ahajournals.org/doi/suppl/10.1161/STR.0000000000000211. The American Heart Association requests that this document be cited as follows: Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL; on behalf of the American Heart Association Stroke Council. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344 e418 doi: 10.1161/STR.0000000000000211. The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit https://professional.heart.org/statements. Select the Guidelines & Statements drop-down menu, then click Publication Development. Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at https://www.heart.org/permissions. A link to the Copyright Permissions Request Form appears in the second paragraph (https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form).


A link to the Copyright Permissions Request Form appears in the second paragraph (https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form). Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association Endorsed by the Society for Academic Emergency Medicine and The Neurocritical Care Society Reviewed for evidence-based integrity and endorsed by the American Association of Neurological Surgeons and Congress of Neurological Surgeons. William J. Powers, MD, FAHA, Chair; Alejandro A. Rabinstein, MD, FAHA, Vice Chair; Teri Ackerson, BSN, RN; Opeolu M. Adeoye, MD, MS, FAHA; Nicholas C. Bambakidis, MD, FAHA; Kyra Becker, MD, FAHA; Jos Biller, MD, FAHA; Michael Brown, MD, MSc; Bart M. Demaerschalk, MD, MSc, FAHA; Brian Hoh, MD, FAHA; Edward C. Jauch, MD, MS, FAHA; Chelsea S. Kidwell, MD, FAHA; Thabele M. Leslie-Mazwi, MD; Bruce Ovbiagele, MD, MSc, MAS, MBA, FAHA; Phillip A. Scott, MD, MBA, FAHA; Kevin N. Sheth, MD, FAHA; Andrew M. Southerland, MD, MSc, FAHA; Deborah V. Summers, MSN, RN, FAHA; David L. Tirschwell, MD, MSc, FAHA; on behalf of the American Heart Association Stroke Council 2019 American Heart Association, Inc. Stroke is available at https://www.ahajournals.org/journal/str AHA/ASA Guideline Powers et al 2019 Guidelines for Management of AIS e345 when appropriate. The current final document was approved by all members of the writing group except when relationships with industry precluded members from voting and by the governing bodies of theAHA. These guidelines use theAmerican College of Cardiology/AHA 2015 Class of Recommendations and Level of Evidence and the new AHA guidelines format. Results These guidelines detail prehospital care, urgent and emergency evaluation and treatment with intravenous and intra-arterial therapies, and in-hospital management, including secondary prevention measures that are appropriately instituted within the first 2 weeks.


Results These guidelines detail prehospital care, urgent and emergency evaluation and treatment with intravenous and intra-arterial therapies, and in-hospital management, including secondary prevention measures that are appropriately instituted within the first 2 weeks. The guidelines support the overarching concept of stroke systems of care in both the prehospital and hospital settings. Conclusions These guidelines provide general recommendations based on the currently available evidence to guide clinicians caring for adult patients with acute arterial ischemic stroke. In many instances, however, only limited data exist demonstrating the urgent need for continued research on treatment of acute ischemic stroke. (Stroke. 2019;50:e344 e418. Key Words: AHA Scientific Statements critical care disease management emergency medical services secondary prevention stroke therapeutics See related article, p 3331 New high-quality evidence has produced major changes in the evidence-based treatment of acute ischemic stroke (AIS) since the publication of the guidelines for the early management of patients with acute ischemic stroke in 2013.1 Much of this new evidence has been incorporated into American Heart Association (AHA) focused updates, guidelines, or scientific statements on specific topics relating to the management of patients with AIS since 2013. The purpose of these guidelines is to provide an up- to-date comprehensive set of recommendations for clinicians caring for adult patients with acute arterial ischemic stroke in a single document. These guidelines address prehospital care, ur- gent and emergency evaluation and treatment with intravenous (IV) and intra-arterial therapies, and in-hospital management, including secondary prevention measures that are often begun during the initial hospitalization. We have restricted our recom- mendations to adults and to secondary prevention measures that are appropriately instituted within the first 2 weeks.